IRVINE, Calif., Sept. 07, 2017 -- Khang & Khang LLP (the “Firm”) announces the filing of a securities class action lawsuit against Vitamin Shoppe, Inc. (“Vitamin Shoppe” or the “Company”) (NYSE:VSI). Investors who purchased or otherwise acquired shares between March 1, 2017 and August 6, 2017, inclusive (the “Class Period”), are encouraged to contact the Firm in advance of the October 27, 2017 lead plaintiff motion deadline.
If you purchased Vitamin Shoppe shares during the Class Period, please contact Joon M. Khang, Esq., of Khang & Khang LLP, 4000 Barranca Parkway, Suite 250, Irvine, CA 92604, by telephone at (949) 419-3834, or by e-mail at [email protected].
There has been no class certification in this case yet. Until certification occurs, you are not represented by an attorney. You may choose to take no action and remain a passive class member as well.
According to the Complaint, throughout the Class Period, Vitamin Shoppe made false and/or misleading statements, and/or failed to disclose: that the Company’s retail segment was continuing to dramatically decline; that its ongoing “reinvention plan” had been unsuccessful and brought more than $168 million in goodwill impairment, and it was not properly recognizing that impairment charge; and that as a result of the above, the Company’s public statements were materially false and misleading at all relevant times. On May 10, 2017, Vitamin Shoppe released first quarter 2017 financial results that were lower than market expectations and slashed its fiscal 2017 guidance by 45%, yet claimed the “reinvention plan” was still succeeding. Following this news, the Company’s stock price fell dramatically. On August 9, 2017, the Company announced that it was taking a $168.1 million impairment charge on the goodwill being carried on its books associated with its retail segment, and that it would report a loss per share of $6.73. Also, citing “the potential increase in variability of the Company’s results due to the number of initiatives being launched in the back half of the year,” Vitamin Shoppe dropped its fiscal 2017 earnings per share guidance altogether. When this news was announced to the public, the Company’s shares declined in value materially, which caused investors harm according to the Complaint.
If you wish to learn more about this lawsuit, or if you have any questions concerning this notice or your rights, please contact Joon M. Khang, Esq., a prominent litigator for almost two decades, by telephone at (949) 419-3834, or by e-mail at [email protected].
This press release may constitute Attorney Advertising in some jurisdictions.
Contact Joon M. Khang, Esq. Telephone: 949-419-3834 Facsimile: 949-225-4474 [email protected]


Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook
Apple Turns 50: From Garage Startup to AI Crossroads
Novartis to Acquire Biotech Firm Excellergy in $2 Billion Deal
Nomura Upgrades PDD Holdings to Buy, Calls Stock Too Cheap to Ignore
TSMC Japan's Second Fab to Produce 3nm Chips by 2028
Luxury Car Sales in the Middle East Take a Hit Amid Iran War
SpaceX Eyes Historic IPO at $1.75 Trillion Valuation
Russell 1000 Companies Hit $2.2T Cash Record While Aggressively Reinvesting in Growth
Europe's Aviation Sector on Track to Meet 2025 Green Fuel Mandate
Norma Group Posts Revenue Decline in 2025, Eyes Modest Recovery in 2026
SoftwareONE Posts 22.5% Revenue Surge in 2025 on Crayon Acquisition
Cybersecurity Stocks Tumble After Anthropic's Claude Mythos AI Leak Sparks Market Fears
Ukrainian Drones and the #MadeByHousewives Movement: Kyiv Fires Back at Rheinmetall CEO
Trump Administration Plans 100% Tariffs on Pharmaceutical Imports
Jefferies Upgrades Sodexo to Buy With €55 Target After Historic CEO Appointment
Cathay Pacific Holds Firm on Flight Capacity Amid Middle East Conflict and Rising Fuel Costs
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure 



